Why is Parmax Pharma falling/rising?

As of 11-Aug, Parmax Pharma Ltd's stock price is currently at 39.77, reflecting an increase of 0.8, or 2.05%. The stock has shown strong performance recently, gaining 12.34% over the last two days and outperforming its sector by 1.14%. Despite a year-to-date decline of 10.12%, the stock has generated a notable return of 13.79% over the past year, indicating resilience against broader market trends. The company has also reported positive results for the last three consecutive quarters, with net sales for the first nine months higher at Rs 20.39 crore. However, it faces challenges due to a negative book value and weak long-term growth, which may temper investor enthusiasm.
In the broader market context, the stock's short-term performance contrasts sharply with the benchmark, as it has increased by 5.60% over the past week while the Sensex has declined by 0.51%. This divergence highlights Parmax Pharma's ability to attract investor interest despite the overall market's struggles, as evidenced by a significant rise in delivery volume. However, the stock's long-term fundamentals remain a concern, with weak operating profits and a poor EBIT to interest ratio, suggesting that while the stock may be rising in the short term, its long-term outlook could be precarious.